Welcome to our dedicated page for Alvotech news (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech stock.
Alvotech develops and manufactures biosimilar medicines for global markets. Company news centers on its approved and marketed biosimilars to Humira, Stelara, Simponi, Eylea and Prolia/Xgeva, along with disclosed candidates for autoimmune disorders, eye disorders, osteoporosis, respiratory disease and cancer.
Recurring updates cover financial results, annual reporting, FDA interactions tied to the Reykjavik manufacturing facility, biosimilar study results such as AVT80, supply and commercialization partnerships, intellectual-property settlements, executive changes and manufacturing-platform developments. Alvotech also reports on global commercial reach through partners across the United States, Europe, Japan, China and other international markets.
Alvotech (ALVO) reported that Richard Davies, Deputy Chairman of the Board of Directors, has acquired 19,988 shares at a price of $10.18 per share on May 14, 2025. The total transaction value amounts to approximately $203,477. The transaction was filed with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) as part of the required disclosure for transactions of managers and closely associated persons.
Alvogen Lux Holdings S.ár.l., Alvotech's (ALVO) second-largest shareholder, has acquired 210,000 shares at ISK 1,277.38 per share. The transaction was reported through a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF). Alvogen Lux Holdings' ownership structure consists of CVC (40%), Aztiq (30%), and Temasek (20%) as its largest shareholders.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has announced its participation in the BofA Securities Healthcare Conference 2025 in Las Vegas from May 13-15, 2025. The company's management team will conduct one-on-one meetings and participate in a fireside chat on May 14, 2025, from 11:40 am to 12:10 pm EDT. A live audio webcast of the chat will be available to the public through Alvotech's investor relations website, with a replay accessible for 90 days post-event.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, announced its participation in the BofA Securities Healthcare Conference 2025 in Las Vegas from May 13-15, 2025. The company's management team will conduct one-on-one meetings and participate in a fireside chat on May 14, 2025, at 11:40 am-12:10 pm EDT. The chat will be accessible via live audio webcast on Alvotech's investor relations website, with a replay available for 90 days post-event.
Alvotech (ALVO) announced that its Chairman and CEO, Robert Wessman, has acquired 320,000 shares of the company at a price of ISK 1,255 per share. The transaction was executed at market opening and has been reported to the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) in accordance with regulatory requirements.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has appointed Dr. Balaji V. Prasad as Chief Strategy Officer. Dr. Prasad brings 25 years of pharmaceutical industry experience, combining medical expertise with financial analysis background. He previously served as a director and equities analyst at Barclays, covering US specialty pharma. His credentials include an MD from Bangalore Medical College and an MBA from IIM Ahmedabad.
Prior roles include portfolio management at a Swiss asset management firm and leadership positions at Barclays and Goldman Sachs' India healthcare coverage. Chairman and CEO Róbert Wessman highlighted Dr. Prasad's deep understanding of Alvotech's business and product pipeline as key assets for the company's growth.
Alvotech (NASDAQ: ALVO), Kashiv Biosciences, and Advanz Pharma announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted a marketing application for AVT23, a proposed biosimilar to Xolair® (omalizumab). The biosimilar targets treatments for severe persistent allergic asthma and chronic rhinosinusitis with nasal polyps.
Xolair recorded global sales of $4.4 billion in 2024. The development builds on previous partnerships, including a February 2023 commercialization agreement between Alvotech and Advanz Pharma for AVT23, which was expanded in May 2023 to include five additional biosimilar candidates. Additionally, Alvotech and Kashiv established a licensing agreement for AVT23 in October 2023.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has announced plans to list Swedish Depository Receipts (SDRs) on Nasdaq Stockholm. The listing follows Alvotech's acquisition of Xbrane Biopharma's R&D operations and aims to expand its investor base in Nordic and European markets. The offering includes 441,600 SDRs with an estimated gross proceeds of SEK 30 million, with each SDR representing one share.
The offering price will be set at the lower of the volume-weighted average price or closing price of Alvotech shares on Nasdaq Iceland during the application period (May 9-16, 2025), with a 10% discount and capped at SEK 90 per SDR. Trading is expected to commence on May 19, 2025, under the ticker "ALVO SDB". Existing shareholders will have a one-year free conversion period to convert their shares into SDRs.